Publications Archives - Page 36 of 783

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

by | Jun 20, 2024 | Publications

Oncology (Williston Park). 2024 Jun 10;38(6):239-241. doi: 10.46883/2024.25921023. ABSTRACT The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials. PMID:38899981 | DOI:10.46883/2024.25921023

Identification of therapy-induced clonal evolution and resistance pathways in minimal residual clones in multiple myeloma through single-cell sequencing

by | Jun 20, 2024 | Publications

Clin Cancer Res. 2024 Jun 20. doi: 10.1158/1078-0432.CCR-24-0545. Online ahead of print. ABSTRACT PURPOSE: In multiple myeloma (MM), therapy-induced clonal evolution is associated with treatment resistance and is one of the most important hindrances toward a cure for...

TGF-beta: an active participant in the immune and metabolic microenvironment of multiple myeloma : TGF-beta in the microenvironment of multiple myeloma

by | Jun 20, 2024 | Publications

Ann Hematol. 2024 Jun 20. doi: 10.1007/s00277-024-05843-4. Online ahead of print. ABSTRACT Although substantial quantities of potent therapies for multiple myeloma (MM) have been established, MM remains an incurable disease. In recent years, our understanding of the...

Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers

by | Jun 20, 2024 | Publications

Pharmacoecon Open. 2024 Jun 20. doi: 10.1007/s41669-024-00503-9. Online ahead of print. ABSTRACT BACKGROUND AND OBJECTIVE: This study aimed to assess the cost-effectiveness of two regimens regarded as the standard of care for the treatment of newly diagnosed,...

Houde CA, Khan A, Jacobus SJ, et al. Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus Rvd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (Pts) with newly diagnosed multiple myeloma (NDMM) in the Determination phase 3 trial [abstract]. Blood. 2023;142(suppl 1):4762

by | Jun 20, 2024 | Publications

Blood. 2024 Jun 20;143(25):2676. doi: 10.1182/blood.2024025081. NO ABSTRACT PMID:38900470 | DOI:10.1182/blood.2024025081

Azab AK, Quang P, Azab F, et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012;119(6):1468-1478

by | Jun 20, 2024 | Publications

Blood. 2024 Jun 20;143(25):2675. doi: 10.1182/blood.2024024988. NO ABSTRACT PMID:38900471 | DOI:10.1182/blood.2024024988

« Older Entries

Next Entries »

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

Identification of therapy-induced clonal evolution and resistance pathways in minimal residual clones in multiple myeloma through single-cell sequencing

TGF-beta: an active participant in the immune and metabolic microenvironment of multiple myeloma : TGF-beta in the microenvironment of multiple myeloma

Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers

Azab AK, Quang P, Azab F, et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012;119(6):1468-1478

Recent Content